Mesoblast reports $115M revenue in first year post-FDA approval of Ryoncil, expands trials for serious inflammatory diseases.
Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year after FDA approval of its cell therapy Ryoncil, used for steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expandin...
